Journal of Research in Ayurvedic Sciences

Register      Login

VOLUME 1 , ISSUE 4 ( October-December, 2017 ) > List of Articles

RESEARCH ARTICLE

Clinical Efficacy and Safety of Mahatriphaladya Ghrita in the Management of Allergic Conjunctivitis: A Prospective Open Label Multicenter Study

Alok Srivastav, Sanjaykumar Singh, Vanmala B Wakode, Madan M Padhi

Keywords : Mahatriphaladya Ghrita, Triphala Kwath,Allergic conjunctivitis

Citation Information : Srivastav A, Singh S, Wakode VB, Padhi MM. Clinical Efficacy and Safety of Mahatriphaladya Ghrita in the Management of Allergic Conjunctivitis: A Prospective Open Label Multicenter Study. J Res Ayurvedic Sci 2017; 1 (4):247-253.

DOI: 10.5005/jp-journals-10064-0025

License: CC BY-NC 3.0

Published Online: 00-12-2017

Copyright Statement:  Copyright © 2017; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Introduction: Allergic conjunctivitis is a mild, nonspecific inflammation of the conjunctiva due to allergy with symptoms of conjunctival congestion, mild papillary response, and intense itching without any known specific condition for pathology to develop or with undetermined etiology that is mostly and easily attributed to allergy. Aims and objectives: To evaluate the efficacy and safety of Mahatriphaladya Ghrita and Triphala Kwath (Aschyotana) in patients suffering from allergic conjunctivitis. Materials and methods: A prospective, open label multicenter study was carried out at two peripheral centers of the Central Council for Research in Ayurvedic Sciences (CCRAS). Totally, 54 patients satisfying the selection criteria were enrolled from the outpatient department (OPD) of these centers and were administered Mahatriphaladya Ghrita (15 mL) twice daily on an empty stomach in the morning and 3 hours before meals in the evening with lukewarm water for 12 weeks and Triphala Kvatha (10 drops) Aschyotana twice daily for 12 weeks. All the participants were subjected to complete physical and ophthalmic examination along with blood investigations. Follow-up was done finally after 2 weeks without medication. Laboratory parameters, viz., absolute eosinophil count (AEC), liver function tests, kidney function tests, lipid profile, total leukocyte count (TLC) were assessed at baseline and at the end of the treatment period of 12 weeks (i.e., 84th day). Paired sample t-test was used to compare mean change from baseline to the 84th day on the outcome variables assessed by visual analog scale (VAS, 0–100 mm) and on the laboratory examination. A p-value of <0.05 was considered significant. Results: At the end of 12 weeks, compared with baseline, statistically significant improvement was observed in symptoms, viz., redness, anxiety, lacrimation, photophobia, burning, and foreign body sensation (p < 0.001). The treatment was found to be safe and effective in the subjects of allergic conjunctivitis as all the safety parameters were within the stipulated range. No adverse drug reactions or adverse events were reported during the trial period. Conclusion: Mahatriphaladya Ghrita and Triphala Kwath (Aschyotana) administered in the above-mentioned dose were found effective and safe in patients suffering from allergic conjunctivitis.


PDF Share
  1. Khurana AK. Comprehensive ophthalmology, 4th ed. New Delhi: New Age International (P) Limited Publishers; 2009. ch.4, pp. 73-74.
  2. Bielory L, Friedlaender MH. Allergic conjunctivitis. Immunol Allergy Clin North Am 2008 Feb;28(1):43-58, vi.
  3. Select Research Papers on Ayurvedic Ophthalmology. CCRAS Publication, effect daruharidra, 2008. pp. 1-2.
  4. Whitcup SM. Recent advances in ocular therapeutics. Int Ophthalmol Clin 2006 Oct;46(4):1-6.
  5. Ono SJ, Abelson MB. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol 2005 Jan;115(1):118-22.
  6. Anonymous. The Ayurvedic Pharmacopoeia of India. Ministry of Health and Family Welfare, Govt. of India, New Delhi, Part II, vol. II, 1st ed., Delhi: The Controller of Publications; 2010. pp. 102-104.
  7. Sushruta Samhita, with the Nibandhasangraha commentary of Sri Dalhanacharya edited by Vaidya Jadavaji Trikamji, Chaukhamba Orientalia Varanasi, Uttara Tantra 6/5. p. 603.
  8. Alexander M, Berger W, Buchholz P, Wolt J, Burk C, Lee J, Arbuckle R, Abetz L. The reliability, validity and preliminary responsiveness of the Eye Allergy Patient Impact Questionnaire (EAPIQ). Health Qual Life Outcomes. 2005 Oct;3:67.
  9. Bhavaprakasa Nighantu, Sri Bhavamisra, edited by Pandey GS, 7th ed. Chaukhamba Bharati Academy Ghrtavarga. p. 777.
  10. Bhavaprakasa Nighantu, Sri Bhavamisra, edited by Pandey GS, 7th ed. Chaukhamba Bharati Academy Guduchadivarga. p. 5.
  11. Bhavaprakasa Nighantu, Sri Bhavamisra, edited by Pandey GS, 7th ed. Chaukhamba Bharati Academy Guduchadivarga. p. 9.
  12. Bhavaprakasa Nighantu, Sri Bhavamisra, edited by Pandey GS, 7th ed. Chaukhamba Bharati Academy Guduchadivarga. p. 10.
  13. Bhavaprakasa Nighantu, Sri Bhavamisra, edited by Pandey GS, 7th ed. Chaukhamba Bharati Academy Guduchadivarga. p. 429.
  14. Bhavaprakasa Nighantu, Sri Bhavamisra, edited by Pandey GS, 7th ed. Chaukhamba Bharati Academy Guduchadivarga. p. 392.
  15. Anonymous. The Ayurvedic Pharmacopoeia of India. Ministry of Health and Family Welfare, Govt. of India, New Delhi, Part I Vol. II, Delhi: The Controller of Publications; 2003. pp. 168-169.
  16. Ashtanga Hridaya Vagbhat, Motilal Banarasi Das Nepalikhapra Varanasi Sutra Stana, 23/1, edition 1963. p. 170.
  17. Vangasena Samhita, Edited by Dr. Ram Kumar Rai Netra Roga Adhikar 47, 298. 1st ed. 1983. p. 602, 623.
  18. Sharanghdhara Samhita Aachary Sharangadhar. Chaukhamba orientalia, Varanasi uttar Khanda, 13/20, 2nd ed. 1998. p. 482.
  19. Bhavaprakasa Nighantu, Sri Bhavamisra, edited by Pandey GS, 7th ed. Chaukhamba Bharati Academy. p. 12.
  20. Gopinathan G, Dhiman KS. Triphala in eye diseases: a critical review. J Homeop Ayurv Med 2013 Jul;2:2.
  21. Belapurkar P, Goyal P, Tiwari-Barua P. Immunomodulatory effects of triphala and its individual constituents: a review. Indian J Pharm Sci 2014 Nov-Dec;76(6):467-475.
PDF Share